^
    Back
    Association details:
    Biomarker:HLA-A*02:01
    Cancer:Uveal Melanoma
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor) +
    Kimmtrak (tebentafusp-tebn) (CD3 agonist, gp100 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update

    Published date:
    06/03/2022
    Excerpt:
    Previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma should be offered tebentafusp.
    DOI:
    10.1200/JCO.22.00944
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2022
    Title:

    832P - Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)

    Published date:
    09/05/2022
    Excerpt:
    Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)...Total mOS was numerically higher in group 2 (55.6 v 37.6 mo). ORR for PD1+IPI was 15% v 6%. Stable disease (SD) was more common in tebe (38% v 39%) than PD1+IPI (12% v 30%). DCR for tebe was similar in Group 1 and 2 (46% v 45%)….Tebe was active prior to or after PD1+IPI (DCR 46% v 45%). PD1+IPI showed similar efficacy in Group 1 and Group 2.